Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment

By Gschwind Liliane   Rollason Victoria   Boehlen Françoise   Rebsamen Michela   Combescure Christophe   Grünenwald Michèle   Matthey Alain   Bonnabry Pascal   Dayer Pierre   Desmeules Jules Alexandre  

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 745-753

Future Medicine

Access to resources Recommend Favorite

In Vivo Animal Models for Investigating Potential CYP3A- and Pgp-Mediated Drug-Drug Interactions

By  

Current Drug Metabolism, Vol. 7, Iss. 7, 2006-10 ,pp. : 687-704

Bentham Science Publishers

Access to resources Recommend Favorite

In Silico Predictions and In Vivo Results of Drug–Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate

By  

Clinical Pharmacology In Drug Development, Vol. 5, Iss. 5, 2016-09 ,pp. : 364-373

John Wiley & Sons Inc

Access to resources Recommend Favorite

General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information

By Ohno Yoshiyuki  

Clinical Pharmacokinetics, Vol. 47, Iss. 10, 2008-01 ,pp. : 669-680

Adis International

Access to resources Recommend Favorite

Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions

By Tod Michel   Goutelle Sylvain   Clavel-Grabit Fannie   Nicolas Grégoire   Charpiat Bruno  

Clinical Pharmacokinetics, Vol. 50, Iss. 8, 2011-08 ,pp. : 519-530

Adis International

Access to resources Recommend Favorite